haleon plc glp-1 receptor agonist medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness GLP-1 receptor agonists | How

How May GIP Enhance the Therapeutic Efficacy of GLP-1

10.1016/j.cct.2024.107692 5 CortesT

Studies suggest GLP-1 receptor agonists may slow kidney function decline, potentially through anti-inflammatory mechanisms alongside improved glycaemic control and blood pressure reduction

These trials have shown reductions in heart failure symptoms and physical limitations and greater improvement in exercise function and have led to growing interest in new ways to address HFpEF, a condition with limited guideline direct medication therapy compared to heart failure with reduced ejection fraction (HFrEF)

By doing so, they help regulate blood sugar levels, slow stomach emptying, and signal the brain that the body is still full

Clinical trials of GLP-1 medications, including the STEP program for semaglutide and SURMOUNT trials for tirzepatide, have documented improvements in physical function scores and quality of life measures